- Home
- XBIO vs BDRX Comparison
XBIO vs BDRX Comparison
Compare XBIO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- BDRX
- Stock Information
- Founded
- XBIO N/A
- BDRX 2000
- Country
- XBIO United States
- BDRX United Kingdom
- Employees
- XBIO N/A
- BDRX N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- BDRX Health Care
- Exchange
- XBIO Nasdaq
- BDRX Nasdaq
- Market Cap
- XBIO 4.2M
- BDRX 3.6M
- IPO Year
- XBIO N/A
- BDRX N/A
- Fundamental
- Price
- XBIO $2.96
- BDRX $1.15
- Analyst Decision
- XBIO Hold
- BDRX
- Analyst Count
- XBIO 1
- BDRX 0
- Target Price
- XBIO N/A
- BDRX N/A
- AVG Volume (30 Days)
- XBIO 6.9K
- BDRX 3.6M
- Earning Date
- XBIO 05-13-2025
- BDRX 04-11-2025
- Dividend Yield
- XBIO N/A
- BDRX N/A
- EPS Growth
- XBIO N/A
- BDRX N/A
- EPS
- XBIO N/A
- BDRX N/A
- Revenue
- XBIO $2,582,728.00
- BDRX N/A
- Revenue This Year
- XBIO $14.23
- BDRX N/A
- Revenue Next Year
- XBIO $7.14
- BDRX N/A
- P/E Ratio
- XBIO N/A
- BDRX N/A
- Revenue Growth
- XBIO 5.63
- BDRX N/A
- 52 Week Low
- XBIO $2.20
- BDRX $1.01
- 52 Week High
- XBIO $5.20
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- XBIO 48.28
- BDRX 39.66
- Support Level
- XBIO $2.85
- BDRX $1.01
- Resistance Level
- XBIO $3.22
- BDRX $1.26
- Average True Range (ATR)
- XBIO 0.14
- BDRX 0.12
- MACD
- XBIO -0.00
- BDRX 0.01
- Stochastic Oscillator
- XBIO 26.91
- BDRX 15.22
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.